Personal genetics company 23andMe will only sell ancestry reports and raw data as controversy with regulators continues.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
The U.S. government is concerned that some of 23andMe’s health assessments could mislead customers.
Researchers uncover new ties between genetics and skin cancer by mining patients’ medical records.
High-throughput sequencing takes another step into the clinic with first regulatory approvals.
Three large clinical trials show little benefit to analyzing the genes of patients to find the right dose of blood thinners.
For the first time, researchers report that monkeys can use brain implants to control a left and a right arm.
Dimension Therapeutics wants to develop a lifetime fix for hemophilia using gene therapy.
Spark Therapeutics hopes to commercialize multiple gene-based treatments developed at the Children's Hospital of Philadelphia.
Study suggests how brain technology could one day tap into thoughts.
Neuroscientists Daniela Schiller says every time you recall a memory, it changes, and that can be a useful thing.